LCN2 and Crohn disease: Other studies have confirmed the potential usefulness of NGAL measurement in the evaluation of early responses to therapy or in predicting different clinical outcomes with infliximab in Crohn disease [6] and intravenous immunoglobulin infusion in renal disease [23].